|
1
|
Mackman N: New insights into the
mechanisms of venous thrombosis. J Clin Invest. 122:2331–2336.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Branchford BR and Carpenter SL: The role
of inflammation in venous thromboembolism. Front Pediatr.
6(142)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Riva N, Donadini MP and Ageno W:
Epidemiology and pathophysiology of venous thromboembolism:
Similarities with atherothrombosis and the role of inflammation.
Thromb Haemost. 113:1176–1183. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Prandoni P: Links between arterial and
venous disease. J Intern Med. 262:341–350. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Smeeth L, Cook C, Thomas S, Hall AJ,
Hubbard R and Vallance P: Risk of deep vein thrombosis and
pulmonary embolism after acute infection in a community setting.
Lancet. 367:1075–1079. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tichelaar YI, Kluin-Nelemans HJ and Meijer
K: Infections and inflammatory diseases as risk factors for venous
thrombosis. A systematic review. Thromb Haemost. 107:827–837.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tang N, Li D, Wang X and Sun Z: Abnormal
coagulation parameters are associated with poor prognosis in
patients with novel coronavirus pneumonia. J Thromb Haemost.
18:844–847. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Klok FA, Kruip MJHA, van der Meer NJM,
Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J,
Stals MAM, Huisman MV, et al: Incidence of thrombotic complications
in critically ill ICU patients with COVID-19. Thromb Res.
191:145–147. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Saha P, Humphries J, Modarai B, Mattock K,
Waltham M, Evans CE, Ahmad A, Patel AS, Premaratne S, Lyons OTA, et
al: Leukocytes and the natural history of deep vein thrombosis:
Current concepts and future directions. Arterioscler Thromb Vasc
Biol. 31:506–512. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Phillippe HM: Overview of venous
thromboembolism. Am J Manag Care. 23:S376–S382. 2017.PubMed/NCBI
|
|
11
|
Reitsma PH, Versteeg HH and Middeldorp S:
Mechanistic view of risk factors for venous thromboembolism.
Arterioscler Thromb Vasc Biol. 32:563–568. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chirinos JA, Heresi GA, Velasquez H, Jy W,
Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP and Ahn YS:
Elevation of endothelial microparticles, platelets, and leukocyte
activation in patients with venous thromboembolism. J Am Coll
Cardiol. 45:1467–1471. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Levi M, van der Poll T and Büller HR:
Bidirectional relation between inflammation and coagulation.
Circulation. 109:2698–2704. 2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Franco RF, de Jonge E, Dekkers PE,
Timmerman JJ, Spek CA, van Deventer SJ, et al: The in vivo kinetics
of tissue factor messenger RNA expression during human endotoxemia:
Relationship with activation of coagulation. Blood. 96:554–559.
2000.PubMed/NCBI
|
|
15
|
Malaponte G, Polesel J, Candido S,
Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello
L, Mazzarino MC, et al: IL-6-174 G > C and MMP-9-1562 C > T
polymorphisms are associated with increased risk of deep vein
thrombosis in cancer patients. Cytokine. 62:64–69. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang Y, Zhang Z, Wei R, Miao X, Sun S,
Liang G, Chu C, Zhao L, Zhu X, Guo Q, et al: IL (Interleukin)-6
contributes to deep vein thrombosis and is negatively regulated by
miR-338-5p. Arterioscler Thromb Vasc Biol. 40:323–334.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Streiff MB, Agnelli G, Connors JM,
Crowther M, Eichinger S, Lopes R, McBane RD, Moll S and Ansell J:
Guidance for the treatment of deep vein thrombosis and pulmonary
embolism. J Thromb Thrombolysis. 41:32–67. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Martinelli I, Bucciarelli P and Mannucci
PM: Thrombotic risk factors: Basic pathophysiology. Crit Care Med.
38 (Suppl):S3–S9. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shaheen K, Alraies MC, Alraiyes AH,
Christie R and Factor V: Leiden: How great is the risk of venous
thromboembolism? Cleve Clin J Med. 79:265–272. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shiqing W, Shengzhong M, Cheng Z,
Guangqing C and Chunzheng G: Efficacy of low molecular weight
heparin in spinal trauma patients after part concentrated screw
surgery and its influence on blood parameters and the incidence of
deep venous thrombosis. Med Hypotheses. 132(109330)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cirino G, Cicala C, Bucci M, Sorrentino L,
Ambrosini G, DeDominicis G and Altieri DC: Factor Xa as an
interface between coagulation and inflammation. Molecular mimicry
of factor Xa association with effector cell protease receptor-1
induces acute inflammation in vivo. J Clin Invest. 99:2446–2451.
1997.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Borensztajn K, Peppelenbosch MP and Spek
CA: Factor Xa: At the crossroads between coagulation and signaling
in physiology and disease. Trends Mol Med. 14:429–440.
2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bukowska A, Zacharias I, Weinert S, Skopp
K, Hartmann C, Huth C and Goette A: Coagulation factor Xa induces
an inflammatory signalling by activation of protease-activated
receptors in human atrial tissue. Eur J Pharmacol. 718:114–123.
2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Esmon CT: Targeting factor Xa and
thrombin: Impact on coagulation and beyond. Thromb Haemost.
111:625–633. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kikuchi S, Tsukahara K, Sakamaki K, Morita
Y, Takamura T, Fukui K, Endo T, Shimizu M, Sawada R, Sugano T, et
al: Comparison of anti-inflammatory effects of rivaroxaban vs.
dabigatran in patients with non-valvular atrial fibrillation
(RIVAL-AF study): Multicenter randomized study. Heart Vessels.
34:1002–1013. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kyrle PA and Eichinger S: Deep vein
thrombosis. Lancet. 365:1163–1174. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Signorelli SS, Malaponte MG, Di Pino L,
Costa MP, Pennisi G and Mazzarino MC: Venous stasis causes release
of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor
necrosis factor alpha (TNFalpha) by monocyte-macrophage. Clin
Hemorheol Microcirc. 22:311–316. 2000.PubMed/NCBI
|
|
29
|
Kremers BMM, Ten Cate H and Spronk HMH:
Pleiotropic effects of the hemostatic system. J Thromb Haemost.
16:1464–1473. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Brinkmann V: Neutrophil extracellular
traps in the second decade. J Innate Immun. 10:414–421.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fuchs TA, Brill A, Duerschmied D,
Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW,
Hartwig JH and Wagner DD: Extracellular DNA traps promote
thrombosis. Proc Natl Acad Sci USA. 107:15880–15885.
2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Brill A, Fuchs TA, Savchenko AS, Thomas
GM, Martinod K, De Meyer SF, Bhandari AA and Wagner DD: Neutrophil
extracellular traps promote deep vein thrombosis in mice. J Thromb
Haemost. 10:136–144. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Savchenko AS, Martinod K, Seidman MA, Wong
SL, Borissoff JI, Piazza G, Libby P, Goldhaber SZ, Mitchell RN and
Wagner DD: Neutrophil extracellular traps form predominantly during
the organizing stage of human venous thromboembolism development. J
Thromb Haemost. 12:860–870. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Konstantinides SV, Meyer G, Becattini C,
Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings
CS, Jiménez D, et al: 2019 ESC Guidelines for the diagnosis and
management of acute pulmonary embolism developed in collaboration
with the European Respiratory Society (ERS). Eur Heart J.
41:543–603. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shi C, Wang C, Wang H, Yang C, Cai F, Zeng
F, Cheng F, Liu Y, Zhou T, Deng B, et al: The potential of low
molecular weight heparin to mitigate cytokine storm in severe
COVID-19 patients: A retrospective cohort study. Clin Transl Sci:
Sep 3, 2020 (Epub ahead of print).
|
|
36
|
Jeraj L, Jezovnik MK and Poredos P:
Rivaroxaban versus warfarin in the prevention of post-thrombotic
syndrome. Thromb Res. 157:46–48. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bhalla V, Lamping OF, Abdel-Latif A,
Bhalla M, Ziada K and Smyth SS: Contemporary meta-analysis of
extended direct-acting oral anticoagulant thromboprophylaxis to
prevent venous thromboembolism. Am J Med. 133:1074–1081.e8.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Borgel D, Bianchini E, Lasne D, Pascreau T
and Saller F: Inflammation in deep vein thrombosis: A therapeutic
target? Hematology. 24:742–750. 2019.PubMed/NCBI View Article : Google Scholar
|
